BRUSSELS, BELGIUM--(Marketwire - February 29, 2008) - UCB on track: Strong Financials Exceeding Outlook Major Steps Forward in R&D Solid revenue of EUR3.6 billion with net sales of EUR3.2 billion, were driven by outstanding Keppra® sales of more than EUR1 billion, Xyzal® sales growing to EUR168 million, excellent performance of Neupro® with sales of EUR52 million, supported by successful US launch.
